Olga V. Boyko

Moscow, MOW, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)

Results of a 5-year project for the early diagnosis of multiple sclerosis in first-line blood relatives (RADIRS program)

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 08, 2025

Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients

Quantitative analysis of cerebrospinal fluid flow in multiple sclerosis patients

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 08, 2025

Eculizumab in the treatment of neuromyelitis optica spectrum disorder

Eculizumab in the treatment of neuromyelitis optica spectrum disorder

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 08, 2025

Surgical treatment of secondary trigeminal neuralgia

Surgical treatment of secondary trigeminal neuralgia

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: December 18, 2024

Mistakes in the diagnosis of neuromyelitis optic spectrum diseases lead to wrong therapy and deterioration of patients' condition

Mistakes in the diagnosis of neuromyelitis optic spectrum diseases lead to wrong therapy and deterioration of patients' condition

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 23, 2024

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: February 27, 2023

Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial

Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: February 17, 2022

A rare clinical case of comorbidity of early-onset Parkinson's disease and remitting multiple sclerosis

A rare clinical case of comorbidity of early-onset Parkinson's disease and remitting multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 13, 2021

Possibilities of art therapy and color therapy in the rehabilitation of multiple sclerosis

Possibilities of art therapy and color therapy in the rehabilitation of multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: August 13, 2021

Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab

Changes in the quality of life in patients with multiple sclerosis treated with ocrelizumab

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 15, 2020

Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety

Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: January 15, 2020

Influence of psychopathological factors and personality traits on the results of the study of quality of life in patients with multiple sclerosis

Influence of psychopathological factors and personality traits on the results of the study of quality of life in patients with multiple sclerosis

Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Published: June 04, 2019
Showing 1-12 of 18

Last Updated: 09/26/2026